Citius Pharmaceuticals Inc (NASDAQ:CTXR) is a small-cap stock with a market capitalization of USD $26.49M. While investors primarily focus on the growth potential and competitive landscape of the ...

The jump in price for CTXR stock comes alongside an increase in trading. As of this writing, more than 84 million shares of the stock have changed hands. For some context, the company's daily average ...

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) shares jumped 22.12% in after-hours trading to $1.27 on Tuesday, following the company’s fiscal year 2025 business update and the commercial launch of its ...

Fintel reports that on December 30, 2024, D. Boral Capital upgraded their outlook for Citius Pharmaceuticals (NasdaqCM:CTXR) from Hold to Buy. As of December 23, 2024, the average one-year price ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI – Research Report), Tempest Therapeutics (TPST – Research Report) and Citius ...

) has been revised to $6.12 / share. This is an increase of 20.00% from the prior estimate of $5.10 dated April 25, 2026. The price target is an average of many targets provided by analysts. The ...

Citius Pharmaceuticals, Inc. CTXR announced top-line data from the pivotal phase III study evaluating its novel IL-2R immunotherapy, I/ONTAK (E7777), for the treatment of patients with persistent or ...

CTXR is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of CTXR shares has decreased $0.02 since the market last closed. This is a 3.95% ...

Citius Pharmaceuticals Inc. Annual cash flow by MarketWatch. View CTXR net cash flow, operating cash flow, operating expenses and cash dividends.